End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.935 RON | +0.26% | 0.00% | +38.71% |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 326.9 | 341 | 326.3 | 406.8 | 380 | 936.5 |
Enterprise Value (EV) 1 | 452 | 522.1 | 481 | 549.5 | 459.2 | 1,001 |
P/E ratio | 9.53 x | 11.1 x | 12.4 x | 13.6 x | 9.87 x | 11.5 x |
Yield | 2.05% | 5.88% | 0.68% | 0.53% | 1.4% | - |
Capitalization / Revenue | 0.89 x | 0.86 x | 0.94 x | 1.07 x | 0.76 x | 1.52 x |
EV / Revenue | 1.23 x | 1.32 x | 1.39 x | 1.45 x | 0.92 x | 1.63 x |
EV / EBITDA | 7.6 x | 8.27 x | 8.08 x | 9.36 x | 6.65 x | 7.99 x |
EV / FCF | -8.07 x | -10.2 x | 11.8 x | 25.4 x | 7.71 x | -322 x |
FCF Yield | -12.4% | -9.81% | 8.45% | 3.93% | 13% | -0.31% |
Price to Book | 0.69 x | 0.69 x | 0.57 x | 0.67 x | 0.59 x | 1.11 x |
Nbr of stocks (in thousands) | 671,338 | 671,338 | 671,338 | 671,338 | 671,338 | 671,338 |
Reference price 2 | 0.4870 | 0.5080 | 0.4860 | 0.6060 | 0.5660 | 1.395 |
Announcement Date | 29/03/19 | 26/03/20 | 09/04/21 | 27/04/22 | 27/04/23 | 17/04/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 368.7 | 395.1 | 347.2 | 378.8 | 497.3 | 615.3 |
EBITDA 1 | 59.49 | 63.11 | 59.52 | 58.68 | 69.03 | 125.4 |
EBIT 1 | 38.93 | 41.39 | 37.42 | 34.25 | 46.47 | 97.42 |
Operating Margin | 10.56% | 10.47% | 10.78% | 9.04% | 9.34% | 15.83% |
Earnings before Tax (EBT) 1 | 35.09 | 35.18 | 28.33 | 30.3 | 41.9 | 91.52 |
Net income 1 | 34.3 | 30.82 | 26.39 | 29.94 | 38.51 | 81.09 |
Net margin | 9.3% | 7.8% | 7.6% | 7.9% | 7.74% | 13.18% |
EPS 2 | 0.0511 | 0.0459 | 0.0393 | 0.0446 | 0.0574 | 0.1208 |
Free Cash Flow 1 | -56 | -51.22 | 40.65 | 21.61 | 59.6 | -3.112 |
FCF margin | -15.19% | -12.96% | 11.71% | 5.71% | 11.98% | -0.51% |
FCF Conversion (EBITDA) | - | - | 68.3% | 36.84% | 86.33% | - |
FCF Conversion (Net income) | - | - | 154.06% | 72.2% | 154.74% | - |
Dividend per Share 2 | 0.009992 | 0.0299 | 0.003306 | 0.003198 | 0.007922 | - |
Announcement Date | 29/03/19 | 26/03/20 | 09/04/21 | 27/04/22 | 27/04/23 | 17/04/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | 125 | 181 | 155 | 143 | 79.3 | 64.5 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 2.102 x | 2.869 x | 2.599 x | 2.431 x | 1.148 x | 0.5145 x |
Free Cash Flow 1 | -56 | -51.2 | 40.7 | 21.6 | 59.6 | -3.11 |
ROE (net income / shareholders' equity) | 7.71% | 6.36% | 4.89% | 5.06% | 6.18% | 10.2% |
ROA (Net income/ Total Assets) | 3.8% | 3.45% | 2.82% | 2.43% | 3.32% | 5.73% |
Assets 1 | 901.7 | 893.7 | 934.8 | 1,230 | 1,162 | 1,414 |
Book Value Per Share 2 | 0.7000 | 0.7400 | 0.8600 | 0.9000 | 0.9600 | 1.260 |
Cash Flow per Share 2 | 0 | 0 | 0.0100 | 0 | 0 | 0 |
Capex 1 | 64.6 | 69.2 | 48 | 29.1 | 39.9 | 83 |
Capex / Sales | 17.52% | 17.51% | 13.82% | 7.67% | 8.02% | 13.49% |
Announcement Date | 29/03/19 | 26/03/20 | 09/04/21 | 27/04/22 | 27/04/23 | 17/04/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+38.71% | 279M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- ATB Stock
- Financials Antibiotice S.A.